Note 20 - Segment Information

12 Months Ended

Jun. 30, 2024

Notes to Financial Statements

Segment Reporting Disclosure [Text Block]

Note 20 - Segment Information

The Company’s CODM, who is the Company’s Chief Executive Officer, allocates resources and assesses performance based on financial information of the Company. The CODM reviews financial information presented for each reportable segment for purposes of making operating decisions and assessing financial performance.

The Company manages and aggregates its operational and financial information in accordance with two reportable segments: Rx and Consumer Health. The Rx Segment consists of the Company’s prescription products. The Consumer Health Segment contained the Company’s consumer healthcare products. For purposes of determining operating income or loss by segment, the Company allocates common expenses such as corporate administration, executive and board compensation, insurance, and fees associated with being a publicly traded entity, among others, to the Rx Segment. The Rx Segment also includes pipeline research and development. The CODM does not regularly review asset information by segment, accordingly, asset information is not provided by segment.

Select financial information for these segments is as follows:

	Rx			Consumer Health			Consolidated
	(in thousands)
Year Ended June 30, 2024
Net revenue	$	65,183		$	15,819		$	81,002
Loss from operations	$	(1,590	)	$	(3,664	)	$	(5,254	)
Depreciation and amortization	$	5,909		$	1,547		$	7,456
Stock-based compensation expense	$	2,373		$	540		$	2,913
Restructuring costs	$	2,156		$	209		$	2,365
Year Ended June 30, 2023
Net revenue	$	73,799		$	33,600		$	107,399
Loss from operations	$	(7,358	)	$	(9,707	)	$	(17,065	)
Depreciation and amortization	$	6,271		$	1,116		$	7,387
Stock-based compensation expense	$	5,722		$	324		$	6,046
Impairment expense	$	2,730		$	2,975		$	5,705